CTIS2022-502673-41-01进行中（未招募）1 期
A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of CYP-001 in Combination with Corticosteroids vs Corticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host Disease - CYP-GVHD-P2-01
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Male or female subjects 18 years of age or older, Provide written informed consent form and agree to comply with study procedures, Have undergone first allogeneic hematopoietic stem cell transplant (HSCT) to treat a hematologic disease (malignant or non- malignant), from any donor source (matched and mismatched) using bone marrow, peripheral blood stem cells, or cord blood and any conditioning intensity, Have been clinically diagnosed with acute GvHD requiring systemic therapy with CS. Patients can be enrolled with only a clinically established diagnosis. Biopsy of involved organs with acute GvHD is encouraged but is not required and should not delay study entry. Enrollment/randomization includes commitment to continue steroids, HR-aGvHD must meet one of the following clinical features within 72 hours prior to randomization: A.High-risk as per Refined Minnesota Criteria: •Single organ involvement oStage 4 skin oStage 3-4 lower GI oStage 1-4 liver •Multiple organ involvement oStage 1-2 lower GI plus any liver oStage 2 lower GI plus any skin oStage 3-4 lower GI plus any liver or skin oAny three organ involvement OR B.One of the following: •Isolated stage 2 involvement of the lower GI tract •Stage 1 lower GI tract disease with skin involvement, Evidence of myeloid engraftment post allogeneic HSCT defined as three (3) consecutive days of achieving sustained ANC >500 x 10^6/L. Use of G-CSF and blood transfusion is allowed., Life expectancy of at least one month, in the opinion of the investigator., Investigator believes that the subject (or the subject’s legally acceptable representative[s]) understands the nature, scope and possible consequences of the study.
排除标准
- •Has received any systemic treatment for aGvHD other than corticosteroids +/- CNI (prophylaxis or treatment). Treatment with CS is allowed for up to 72 hours prior to Day 0., Known sensitivity to dimethylsulfoxide (DMSO) or any other component of CYP-001., Known or suspected current alcohol or substance abuse problem, in the opinion of the investigator., Received any investigational treatment agent within 30 days or within 5 half-lives of Screening, whichever is greater., Female subject of childbearing potential either not using or not willing to use an acceptable method of contraception to avoid pregnancy during the study and for 6 months after receipt of the last dose of investigational product. All female subjects are assumed to be of childbearing potential except: •Subjects aged > 60 years and postmenopausal. •Subjects aged 45 to 60 years (inclusive) with amenorrhea for = 1 year with documented evidence of follicle-stimulating hormone level > 30 IU/L. If the follicle-stimulating hormone value is not available before randomization, a urine pregnancy test is required. •Subjects who are surgically sterile for at least 3 months before providing informed consent., Pregnant, breastfeeding or not willing to cease breastfeeding., Currently receiving a therapy not permitted during the study., Involved in the planning and / or conduct of the study (applies to Cynata Therapeutics Limited staff, staff at the study site, and third-party vendors)., Clinical presentation of chronic GvHD or overlap syndrome with both acute and chronic features of GvHD, Presence of relapsed primary malignancy since allogeneic HSCT, Have received more than one allogeneic HSCT, Clinically significant respiratory, renal or cardiac disease at screening including any of the following: a.requiring mechanical ventilation or having resting SO2 <90% on pulse oximetry b.serum creatinine >2mg/dL or eGFR <30ml/min (Cockroft Gault equation) c.uncontrolled hypertension d.Congestive heart failure New York Heart Association Class III or IV, Presence of cholestatic disorders or sinusoidal obstructive syndrome/veno-occlusive disease of the liver defined as persistent bilirubin abnormalities not attributable to aGvHD, Presence of any active uncontrolled infection requiring treatment and which in the opinion of the Investigator and/or Study medical monitor is likely to impact on the ability of the subject to participate in the trial. Infections are considered controlled if appropriate therapy has been used and, at the time of screening, no signs of progression are present., Known infection with CMV, EBV, HBV, HCV, HIV or Tuberculosis. If the treatment for CMV, EBV, HBV, HCV has commenced the subject is eligible for study., Any other medical or psychiatric condition which, in the opinion of the Investigator and/or Study medical monitor, makes the subject unsuitable for participation in the study or interfere with interpretation of study data.
研究者
相似试验
进行中（未招募）
不适用
A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Study to Evaluate the Effects of RLY5016 in Heart Failure Patients - PEARL-HFHyperkalemia in heart failure patientsMedDRA version: 9.1Level: LLTClassification code 10020647Term: HyperkalemiaEUCTR2009-009983-29-DERelypsa, Inc.270
进行中（未招募）
不适用
A multicenter study of the safety, efficacy effects on the body of Humira (adalimumab) in children with polyarticular Juvenile Rheumatoid Arthritis (a form of reheumatoid arthritis in children / young people with unknown cause).Polyarticular Juvenile Rheumatoid ArthritisMedDRA version: 14.1Level: LLTClassification code 10036039Term: Polyarticular juvenile rheumatoid arthritis, chronic or unspecifiedSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2011-001661-40-Outside-EU/EEAAbbott Laboratories171
进行中（未招募）
不适用
A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Study to Evaluate the Effects of RLY5016 in Heart Failure Patients - PEARL-HFHyperkalemia in heart failure patientsMedDRA version: 9.1Level: LLTClassification code 10020647Term: HyperkalemiaEUCTR2009-009983-29-CZRelypsa, Inc.270
进行中（未招募）
不适用
A Multicenter, Double-blind, Randomized, Placebo-Controlled Extension Study Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation.HIV-associated lipodystrophyMedDRA version: 9.1Level: LLTClassification code 10024608Term: LipodystrophyEUCTR2007-003233-16-BETheratechnologies Inc.300
尚未招募
3 期
A Study of JT001 (VV116) for the Early Treatment of Mild to Moderate COVID-19PACTR202210559228718Shanghai JunTop Biosciences Co LTD1,310